EGFR Mutations in Lung Cancer: Correlation with ClinicalResponse to Gefitinib Therapy.
Saved in:
| Title: | EGFR Mutations in Lung Cancer: Correlation with ClinicalResponse to Gefitinib Therapy. |
|---|---|
| Authors: | Paez, J. Guillermo, Janne, Pasi A., Lee, Jeffrey C., Tracy, Sean, Greulich, Heidi, Gabriel, Stacey, Herman, Paula, Kaye, Frederic J., Lindeman, Neal, Boggon, Titus J., Naoki, Katsuhiko, Sasaki, Hidefumi, Fujii, Yoshitaka, Eck, Michael J., Sellers, William R., Johnson, Bruce E., Meyerson, Matthew |
| Source: | Science (pre-March 2025). 6/4/2004, Vol. 304 Issue 5676, p1497-1500. 4p. 2 Diagrams, 1 Graph. |
| Subjects: | Protein-tyrosine kinases, Small cell lung cancer, Genetic mutation, Tumors, Cell lines |
| Geographic Terms: | Japan, United States |
| Abstract: | Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene ECFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gef itinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. ECFR mutations were found in additional lung cancer samples from D.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that ECFR mutations may predict sensitivity to gefitinib. [ABSTRACT FROM AUTHOR] |
| Copyright of Science (pre-March 2025) is the property of American Association for the Advancement of Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene ECFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gef itinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. ECFR mutations were found in additional lung cancer samples from D.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that ECFR mutations may predict sensitivity to gefitinib. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 00368075 |
| DOI: | 10.1126/science.1099314 |
